Search
Zanubrutinib
go.drugbank.com/drugs/DB15035ApprovedInvestigationalL10166] which measures the proportion of patients in a trial whose tumour is entirely or partially destroyed by a drug. … [A187967] BTK is an enzyme that plays a role in oncogenic signalling pathways, promoting the survival and proliferation of malignant B cells.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic IndexConestat alfa
go.drugbank.com/drugs/DB09228ApprovedC1 Esterase Inhibitor (Recombinant) is a recombinant analogue of endogenous complement component-1 esterase inhibitor (rhC1INH), purified from the milk of transgenic rabbits. … Additionally, C4 and C2 cleavage occurs resulting in auto-activation of the complement system.
Categories: Drugs Used in Hereditary AngioedemaTyropanoic acid
go.drugbank.com/drugs/DB09340ApprovedThe molecule contains three heavy iodine atoms which obstruct X-rays in the same way as the calcium in bones, which results in a visible image [L1608]. … Tyropanoic acid is a radiocontrast agent used in cholecystography, the X-ray diagnosis of gallstones under the trade names include Bilopaque, Lumopaque, Tyropaque, and Bilopac.
Categories: Compounds used in a research, industrial, or household settingPhenelzine
go.drugbank.com/drugs/DB00780ApprovedInvestigationalPhenelzine, with the formula β-phenylethylhydrazine, is a monoamine oxidase inhibiting antidepressant that is effective in the treatment of panic disorder and social anxiety disorder. … [A15753] It was developed by Parke Davis and originally FDA approved on June 9th, 1961. It is currently approved under prescription by the name of Nardil.
Categories: Monoamine Oxidase A SubstratesSotorasib
go.drugbank.com/drugs/DB15569ApprovedInvestigational[A187550] Mutant KRAS discovered in 1982 but was not considered a druggable target until the mid-2010s.[A235168] It is the first experimental KRAS inhibitor. … [A187547] Sotorasib was granted FDA approval on May 28, 2021,[L34288] followed by the European Commission's approval on January 6, 2022.[L56070]
Idelalisib
go.drugbank.com/drugs/DB09054ApprovedInvestigationalThe PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer … For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other
Categories: Class Ia Phosphatidylinositol 3-Kinase, antagonists & inhibitors, P-glycoprotein substrates with a Narrow Therapeutic IndexTerpin hydrate
go.drugbank.com/drugs/DB13163ApprovedWithdrawnIt was popular in the United States since the late nineteenth century, but was removed from marketed medications in the 1990s after FDA stated that "based on evidence currently available, there are inadequate … Terpin hydrate is an expectorant, commonly used to loosen mucus and ease congestion in patients presenting with acute or chronic bronchitis, and related pulmonary conditions.
Finerenone
go.drugbank.com/drugs/DB16165ApprovedInvestigationalFinerenone, or BAY 94-8862, is a mineralocorticoid receptor antagonist indicated to reduce the risk of sustained decline in glomerular filtration rate, end stage kidney disease, cardiovascular death, heart … [A236544,L34739] Finerenone was granted FDA approval on 9 July 2021,[L34739] followed by the EMA approval on 11 March 2022.[L41449]
Risankizumab
go.drugbank.com/drugs/DB14762ApprovedInvestigationalRisankizumab is a fully humanized IgG1 monoclonal antibody (mAb) directed against interleukin 23 (IL-23). … [L39885] It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019.
Products: SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML, Skyrizi solution for injection in pre-filled pen 150MG/MLFenproporex
go.drugbank.com/drugs/DB01550ApprovedIllicitWithdrawnFenproporex is an orally active stimulant drug, which was developed in the 1960s. It is used as an appetite suppressant and a treatment for obesity. … and safety data, and is listed as a drug in Schedule IV of the Controlled Substances Act.
Products: IFA-DIETY A. P.